Tawfik Haytham O, El-Hamaky Anwar A, El-Bastawissy Eman A, Shcherbakov Kirill A, Veselovsky Alexander V, Gladilina Yulia A, Zhdanov Dmitry D, El-Hamamsy Mervat H
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
Laboratory of Medical Biotechnology, Institute of Biomedical Chemistry, Pogodinskaya St. 10/8, 119121 Moscow, Russia.
Pharmaceuticals (Basel). 2022 Apr 14;15(4):481. doi: 10.3390/ph15040481.
Telomeres serve a critical function in cell replication and proliferation at every stage of the cell cycle. Telomerase is a ribonucleoprotein, responsible for maintaining the telomere length and chromosomal integrity of frequently dividing cells. Although it is silenced in most human somatic cells, telomere restoration occurs in cancer cells because of telomerase activation or alternative telomere lengthening. The telomerase enzyme is a universal anticancer target that is expressed in 85-95% of cancers. is a selective non-nucleoside potent telomerase inhibitor that acts by direct noncompetitive inhibition. Relying on its structural features, three different series were designed, and 30 novel compounds were synthesized and biologically evaluated as telomerase inhibitors using a telomeric repeat amplification protocol (TRAP) assay. Target compounds , , and reported the greatest inhibitory effect on telomerase enzyme with IC values of 1.7, 0.3, and 2.0 μM, respectively, while displayed IC = 0.2 μM. Compounds , , and were subsequently tested using a living-cell TRAP assay and were able to penetrate the cell membrane and inhibit telomerase inside living cancer cells. Compound was tested for cytotoxicity against 60 cancer cell lines using the NCI (USA) procedure, and the % growth was minimally impacted, indicating telomerase enzyme selectivity. To investigate the interaction of compound with the telomerase allosteric binding site, molecular docking and molecular dynamics simulations were used.
端粒在细胞周期的每个阶段对细胞复制和增殖都起着关键作用。端粒酶是一种核糖核蛋白,负责维持频繁分裂细胞的端粒长度和染色体完整性。尽管在大多数人类体细胞中端粒酶处于沉默状态,但由于端粒酶激活或替代性端粒延长,癌细胞中会发生端粒恢复。端粒酶是一种通用的抗癌靶点,在85% - 95%的癌症中表达。[具体药物名称]是一种选择性非核苷类强效端粒酶抑制剂,通过直接非竞争性抑制发挥作用。基于其结构特征,设计了三个不同的系列,并合成了30种新型化合物,使用端粒重复序列扩增协议(TRAP)测定法作为端粒酶抑制剂进行了生物学评估。目标化合物[具体化合物名称1]、[具体化合物名称2]和[具体化合物名称3]对端粒酶的抑制作用最强,IC值分别为1.7、0.3和2.0 μM,而[具体化合物名称4]的IC值为0.2 μM。随后使用活细胞TRAP测定法对化合物[具体化合物名称1]、[具体化合物名称2]和[具体化合物名称3]进行了测试,它们能够穿透细胞膜并在活癌细胞内抑制端粒酶。使用美国国立癌症研究所(NCI)的方法对化合物[具体化合物名称4]针对60种癌细胞系进行了细胞毒性测试,其生长百分比受到的影响最小,表明端粒酶具有选择性。为了研究化合物[具体化合物名称4]与端粒酶变构结合位点的相互作用,使用了分子对接和分子动力学模拟。